[{"orgOrder":0,"company":"Neomorph","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.46,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.46,"dosageForm":"","sponsorNew":"Neomorph \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Novo Nordisk"},{"orgOrder":0,"company":"Neomorph","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Molecular Glue Degrader-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.45,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.45,"dosageForm":"","sponsorNew":"Neomorph \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Biogen"},{"orgOrder":0,"company":"Neomorph","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.6399999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.6399999999999999,"dosageForm":"","sponsorNew":"Neomorph \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Neomorph

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          European Pharma Congress
                          Not Confirmed
                          European Pharma Congress
                          Not Confirmed

                          Details : The collaboration leverages AbbVie's oncology and immunology drug development expertise and Neomorph's leading molecular glue discovery platform.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 23, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : AbbVie Inc

                          Deal Size : $1,640.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          European Pharma Congress
                          Not Confirmed
                          European Pharma Congress
                          Not Confirmed

                          Details : The collaboration aims to leverage Neomorph's proprietary molecular glue discovery platform to expedite the identification and validation of new small-molecule therapeutics for Alzheimer’s disease.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 29, 2024

                          Lead Product(s) : Molecular Glue Degrader-based Therapy

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Biogen

                          Deal Size : $1,450.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          European Pharma Congress
                          Not Confirmed
                          European Pharma Congress
                          Not Confirmed

                          Details : The collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 26, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Novo Nordisk

                          Deal Size : $1,460.0 million

                          Deal Type : Collaboration

                          blank